Health · Medical Research · 14 hrs ago
Queensland farmer hopes MND trial can give her more time with family
Kilkivan farmer Julianne McLean, 49, was diagnosed with motor neurone disease in August and hopes to take part in a new clinical trial.
MND damages nerve cells in the brain and spinal cord that control movement, causing muscle weakness and loss of function.
There is no cure, and average survival is about three to five years after diagnosis, according to a Queensland neurologist.
The proposed therapy, called NUN-004, is designed to protect these nerve cells and help repair connections between the brain, spinal cord and muscles.
A 75-person phase 2 trial is due to advance next year, after 25 years of research at the University of Queensland.
Recruitment is under way, and the trial is planned for sites on the Sunshine Coast, in Brisbane, Perth, Sydney and Newcastle.
The trial will test whether the therapy can slow MND or restore function, but its effects are not yet known.
Julianne McLean, a 49-year-old Queensland cattle farmer with motor neurone disease, hopes to join a clinical trial that may give her more time with her family.
The phase 2 trial will test a therapy designed to slow MND progression and restore function.
The planned 75-person trial is expected to roll out at hospitals in Queensland, Brisbane, Perth, Sydney and Newcastle.
The therapy grew out of 25 years of University of Queensland research into how nerve cells communicate and repair themselves.
There is no cure for MND, and the article says average survival is about three to five years.
- Who
- Julianne McLean, a 49-year-old cattle farmer from Kilkivan, Queensland, hopes to take part in the trial.
- What
- A 75-person phase 2 clinical trial will test a therapy intended to halt MND progression and restore function.
- When
- The trial is due to advance to phase 2 next year.
- Where
- It is planned for Sunshine Coast University Hospital and sites in Brisbane, Perth, Sydney and Newcastle.
- Why
- McLean hopes the trial could give her more time with her family; the therapy aims to protect movement-controlling nerve cells and repair damaged connections.
This story does not have two clearly opposing sides.
McLean was diagnosed with motor neurone disease.
The therapy is due to advance to a 75-person phase 2 clinical trial.
- Patient
- Julianne McLean, 49
- Home
- Kilkivan, about 230 kilometres north of Brisbane
- Trial size
- 75 people
- Research
- 25 years at the University of Queensland
- Therapy
- NUN-004, a protein-based treatment designed to inhibit the EphA4 receptor
What people are saying
I'm just trying to stay focused on enjoying each day as much as possible.
Developments like this provide genuine reasons for hope.
Currently, we don't have a great understanding of what causes it.